Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

SITC 2022 and Checkpoint Inhibitors View overview page

4:37
Treating PD-L1-positive NSCLC with immunotherapy alone vs chemoimmunotherapy
Biagio Ricciuti • 17 Nov 2022
6:26
Acquired mechanisms of resistance to PD-(L)1 blockade in NSCLC
Biagio Ricciuti • 17 Nov 2022
0:21
Identifying and managing patients who develop ICI-associated acute kidney injury
Shruti Gupta • 16 Nov 2022
0:59
Remaining challenges in the field of onco-nephrology
Shruti Gupta • 16 Nov 2022
0:59
Decreasing the risk of immunotherapy-related kidney damage
Shruti Gupta
1:05
Improving outcomes in ICI-associated acute kidney injury
Shruti Gupta • 16 Nov 2022
2:11
Acute kidney injury in patients receiving immune checkpoint inhibitors
Shruti Gupta • 16 Nov 2022
2:28
Targeting cold tumors with anti-PVRIG immunotherapy
Eran Ophir • 26 Oct 2022
1:29
COM701 & nivolumab in patients with metastatic MSS-CRC & liver metastases
Michael Overman • 9 Nov 2022
3:48
Enhancing immunotherapies with high endothelial venules
Lucas Blanchard • 21 Nov 2022
4:35
Neoadjuvant checkpoint inhibition in NSCLC
Biagio Ricciuti • 17 Nov 2022
7:12
TAP2 downregulation enables immune evasion in NSCLC tumors
Kishu Ranjan • 27 Oct 2022
1:54
The correlation between composition of the gut microbiota with anti-PD-1 efficacy in cancer patients
Saman Maleki • 2 Nov 2022
10:24
Enhancing PD-1 blockade by inhibiting PKM2 activity in the pentose phosphate pathway
Geoffrey Markowitz • 8 Nov 2022
5:24
Clinical applications of pentose phosphate pathway activation in immunotherapy
Geoffrey Markowitz • 8 Nov 2022
2:16
Landscape analysis of neoepitope-specific T-cell responses depending on clinical benefit from ICIs
Cristina Puig Saus • 31 Oct 2022
The content of VJOncology is intended for healthcare professionals